WMUK is pleased to announce a new five year strategic alliance with Dendrite Clinical Systems, to help drive forward research into Waldenstrom's macroglobulinaemia through the WMUK Rory Morrison Registry.
This will provide a stable and secure basis for enabling WMUK to access specialist skills in the development, maintenance, hosting, support and reporting on multiple national and international disease registers.
The WMUK Rory Morrison Registry, which was started in 2016 and contains data about over 1000 people with WM. It is used by over 200 people to regularly report patient outcome measures. This means that the Registry is an unrivalled source of post hoc data about not only the treatment of WM submitted by 24 clinical centres.
The Registry is a key element in WMUK’s objective to support people with WM and their carers to a better life with WM. The Registry will support research into improved treatments and outcomes and research into the repurposing of existing drugs and development of new drug therapies.
Dendrite Clinical Systems is a specialised company providing products and services to support new and existing disease specific registers that play a key role in supporting clinical research and discovery through specialist reporting capabilities.
The strategic alliance puts certainty around the technology and supply arrangements to support the Rory Morrison Registry.